A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa

被引:27
作者
MadarasKelly, KJ
Larsson, AJ
Rotschafer, JC
机构
[1] ST PAUL RAMSEY MED CTR,SECT CLIN PHARM,ST PAUL,MN 55101
[2] IDAHO STATE UNIV,COLL PHARM,POCATELLO,ID 83209
[3] UNIV MINNESOTA,COLL PHARM,MINNEAPOLIS,MN 55455
关键词
D O I
10.1093/jac/37.4.703
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The greater potency of ciprofloxacin in vitro to that of ofloxacin against Pseudomonas aeruginosa may be potentially offset by the more favorable pharmacokinetic profile of the latter drug. In order to test this hypothesis, we generated time concentration kill curves for P. aeruginosa ATCC 27853 and a clinical isolate P. aeruginosa PSA 9258 using an in-vitro model to simulate the pharmacokinetic characteristics found in vitro for ciprofloxacin at a peak concentration (CPmax) of 5 mg/L and an elimination T-1/2, of 4.5 h, and ofloxacin at a CPmax of 5 mg/L and a T-1/2 of both 4.5 h and 6 h, and at a CPmax of 8.0 mg/L and a T-1/2 of 6 h. A 3 log(10) kill (T3 kill) of P. aeruginosa ATCC 27853 was achieved in 0.15 h by ciprofloxacin and of P. aeruginosa PSA 9258 in 0.09 h. Ofloxacin at a CPmax of 8 mg/L and T-1/2 of 6 h achieved a T3 kill of P. aeruginosa ATCC 27853 in 0.74 h and of P. aeruginosa PSA 9258 in 0.16 h. The area under the kill curve (AUKC) was 1.10 x 10(4) and 1.96 x 10(3) mL-h/cfu for ciprofloxacin against P. aeruginosa ATCC 27853 and P. aeruginosa PSA 9258, respectively and that of ofloxacin at CPmax 8 mg/L and a T-1/2 of 6 h was 9.78 x 10(4) and 2.20 x 10(4) mL-h/cfu respectively. Significant differences (P greater than or equal to 0.05) were evident between ciprofloxacin and all ofloxacin regimens against P. aeruginosa ATCC 27853 but not against P. aeruginosa PSA 9258. There was a poor correlation (r = 0.22) between the AUKC and area under the time concentration curve (AUG) for P. aeruginosa ATCC 27853 but a strong correlation (r = 0.96) between the AUKC and area under the inhibitory curve (AUIC). Similar results were obtained for P. aeruginosa PSA 9258 for which the correlation between AUKC and AUC was weak (r = 0.10) whereas that between the AUKC and AUIC was strong (r = 0.93). When the data for both P. aeruginosa were combined, a correlation coefficient of r = 0.04 for AUC and r = 0.80 for AUIC was found. These limited data suggest that fluoroquinolones can be compared using the AUIC for specific bacterial isolates. In addition, the larger AUG, higher CP, and longer T-1/2 of ofloxacin in vivo did not fully compensate for the intrinsic differences in the antibiotic susceptibility against P. aeruginosa.
引用
收藏
页码:703 / 710
页数:8
相关论文
共 17 条
[1]  
[Anonymous], CLIN PHARMACOKINETIC
[2]  
DUNCAN D. B., 1951, Virginia Journal of Science, V2, P171
[3]   PHARMACODYNAMICS OF INTRAVENOUS CIPROFLOXACIN IN SERIOUSLY ILL-PATIENTS [J].
FORREST, A ;
NIX, DE ;
BALLOW, CH ;
GOSS, TF ;
BIRMINGHAM, MC ;
SCHENTAG, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1073-1081
[4]  
HERMAN VK, 1991, ANN M AM SOC EXP MIC
[5]  
JUST PM, 1993, PHARMACOTHERAPY S2, V13, P4
[6]   OFLOXACIN CLINICAL PHARMACOKINETICS [J].
LAMP, KC ;
BAILEY, EM ;
RYBAK, MJ .
CLINICAL PHARMACOKINETICS, 1992, 22 (01) :32-46
[7]  
NIGHTINGALE CH, 1993, PHARMACOTHERAPY S2P2, V13, P34
[8]  
SAWCHUK RJ, 1977, CLIN PHARMACOL THER, V21, P362
[9]  
Schentag Jerome J., 1993, P259
[10]   MATHEMATICAL EXAMINATION OF DUAL INDIVIDUALIZATION PRINCIPLES (I) - RELATIONSHIPS BETWEEN AUC ABOVE MIC AND AREA UNDER THE INHIBITORY CURVE FOR CEFMENOXIME, CIPROFLOXACIN, AND TOBRAMYCIN [J].
SCHENTAG, JJ ;
NIX, DE ;
ADELMAN, MH .
DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (10) :1050-1057